타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ breast cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Stable linker, DAR ~3.5 |
Positioning Known limitation | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). |
Positioning Development positioning | 2L |
Technology Payload | DM1 (maytansine derivative) |
Technology Linker | Non-cleavable stable thioether MCC |
MoA Mechanism | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. |
MoA Biomarker | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). |
Toxicology Species | Cynomolgus monkey, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity |
Toxicology CRS | Minimal |
Clinical Safety signal | Thrombocytopenia, hepatotoxicity |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | In vitro |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Kadcyla (ado-trastuzumab emtansine) |
Overview Company | Roche / Genentech |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | HER2+ breast cancer |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Stable linker, DAR ~3.5 |
Positioning Known limitation | HER2 downregulation, lysosomal trapping, and efflux; superseded in 2L HER2+ mBC by trastuzumab deruxtecan (DESTINY-Breast03). |
Positioning Development positioning | 2L |
Technology Payload | DM1 (maytansine derivative) |
Technology Linker | Non-cleavable stable thioether MCC |
MoA Mechanism | Ado-trastuzumab emtansine (T-DM1) binds HER2 on tumor cells, is internalized, and MMAE is released after lysosomal degradation of the antibody in the non-cleavable SMCC linker system. MMAE disrupts microtubules, causing G2/M arrest and apoptosis. |
MoA Biomarker | HER2 overexpression/amplification (IHC 3+ or ISH+ per label). |
Toxicology Species | Cynomolgus monkey, Rat |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Thrombocytopenia, hepatotoxicity |
Toxicology CRS | Minimal |
Clinical Safety signal | Thrombocytopenia, hepatotoxicity |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | In vitro |
추천 비교
추천 비교